Your browser doesn't support javascript.
loading
Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency / 中国当代儿科杂志
Article de Zh | WPRIM | ID: wpr-971064
Bibliothèque responsable: WPRO
ABSTRACT
Phosphomannomutase 2 deficiency is the most common form of N-glycosylation disorders and is also known as phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG). It is an autosomal recessive disease with multi-system involvements and is caused by mutations in the PMM2 gene (OMIM: 601785), with varying severities in individuals. At present, there is still no specific therapy for PMM2-CDG, and early identification, early diagnosis, and early treatment can effectively prolong the life span of pediatric patients. This article reviews the advances in the diagnosis and treatment of PMM2-CDG.
Sujet(s)
Mots clés
Texte intégral: 1 Indice: WPRIM Sujet Principal: Troubles congénitaux de la glycosylation / Mutation Limites du sujet: Child / Humans langue: Zh Texte intégral: Chinese Journal of Contemporary Pediatrics Année: 2023 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Troubles congénitaux de la glycosylation / Mutation Limites du sujet: Child / Humans langue: Zh Texte intégral: Chinese Journal of Contemporary Pediatrics Année: 2023 Type: Article